Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
The myotonic muscle disorders compose a group of disorders characterized by muscle stiffness, pain, and sometimes weakness, which may be intermittent or constant. The primary periodic paralyses are rare inherited disorders associated with attacks of muscle paralysis. Depending on the specific disorder, attacks may last minutes, hours, or days, and some are associated with fixed weakness. The myotonic disorders and periodic paralyses are grouped together as some of them overlap with each other, and all are “channelopathies” associated with mutations of muscle sodium, calcium, potassium, or chloride channels.
Evaluation of these disorders in the electromyography (EMG) laboratory is particularly gratifying, as the EMG accompaniment of myotonia is easily recognized by the experienced electromyographer. Clinically, myotonia is characterized by delayed muscle contraction after activation. Myotonia can also be demonstrated after percussion of the muscle. On EMG, myotonic discharges produce a distinctive revving engine sound. This results from the spontaneous firing of muscle fibers that wax and wane in frequency and amplitude, producing this unmistakable sound ( Fig. 39.1 ). The myotonic potential may take the form of either a positive wave or a brief spike potential, thus identifying the source generator as a muscle fiber. Myotonia can be induced by mechanical stimulation, such as percussion of the muscle or movement of the EMG needle or may follow voluntary muscle contraction. Clinically, myotonia is noted most frequently in the myotonic muscle disorders and in some of the periodic paralysis syndromes ( Box 39.1 ). Patients describe an inability to relax their muscles after contraction, such as during hand grip. In addition, myotonia may be experienced by the patient as muscle stiffness.
Inherited myotonic muscle/periodic paralysis disorders
Dystrophic myotonic muscle disorders
Myotonic dystrophy, types 1 and 2
Nondystrophic myotonic muscle disorders/periodic paralysis syndromes
Chloride channel disorders
Autosomal dominant myotonia congenita (Thomsen)
Autosomal recessive myotonia congenita (Becker)
Sodium channel disorders
Paramyotonia congenita (Eulenburg)
Hyperkalemic periodic paralysis (±myotonia)
Sodium channel myotonia congenita
Hypokalemic periodic paralysis type 2 (rare form)
Andersen-Tawil syndrome (no myotonia)
Hypokalemic periodic paralysis, type 1 (calcium channel, no myotonia)
Schwartz-Jampel syndrome
Acquired periodic paralysis disorders
Secondary hyperkalemic periodic paralysis (may be associated with myotonia) may be seen in association with the following:
Renal failure
Adrenal failure
Hypoaldosteronism
Metabolic acidosis
Secondary hypokalemic periodic paralysis (not associated with myotonia) may be seen in association with:
Hyperthyroidism, especially in Asian adult males
Primary hyperaldosteronism
Diuretics
Inadequate potassium intake
Chronic licorice ingestion
Excessive potassium loss through sweat
Gastrointestinal or renal potassium wasting
Steroid use
Muscle disorders associated with electromyographic myotonia
Metabolic: acid maltase deficiency
Inflammatory: polymyositis
Congenital: myotubular myopathy, myofibrillar myopathy
Associated with systemic disorders: malignant hyperpyrexia
Drug-induced hypothyroidism
Drugs that unmask or precipitate myotonia either clinically or on electromyographic examination
Clofibrate
Propranolol
Fenoterol
Terbutaline
Colchicine
Penicillamine
Cyclosporin
Hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (lipid-lowering agents)
Traditionally, the myotonic muscle disorders have been classified into those with dystrophic changes on muscle biopsy, such as the myotonic dystrophies, resulting in weakness, and those without dystrophic changes, such as myotonia congenita and paramyotonia congenita, where weakness is generally not a feature. Myotonia also occurs in several of the periodic paralysis syndromes, both inherited and acquired, as well as on the EMG examination in some metabolic, inflammatory, congenital, and toxic myopathies, although clinical myotonia is generally not apparent. Myotonia can be unmasked or precipitated by various drugs. Very rarely, myotonic discharges are noted on EMG examination in disorders of nerve associated with severe denervation. Although a single, brief run of myotonia may be seen in denervating disorders, it is never the predominant waveform. Neuromyotonia, a rare phenomenon associated with peripheral nerve as opposed to muscle disorders, may result in a delay in muscle relaxation. However, this can be distinguished from myotonia in the EMG laboratory by the spontaneous firing of motor unit action potentials (MUAPs) as opposed to muscle fiber action potentials .
Genetic linkage and mutational analyses have identified the molecular basis for several of the myotonic muscle disorders and the periodic paralysis syndromes, resulting in the classification of these disorders based on a specific ion channel or protein kinase defect. However, this still leaves a substantial number of patients in whom the diagnosis rests on clinical and electrophysiologic findings alone.
Table 39.1 reviews the classification of these disorders based on clinical, electrophysiologic, and available molecular findings. The electrophysiologic evaluation is directed toward answering several key questions to arrive at the correct diagnosis, including whether myotonia is present or not. To answer these questions, a variety of tests can be performed in the EMG laboratory to distinguish among the dystrophic and nondystrophic myotonic muscle disorders, the periodic paralysis syndromes, and other disorders of muscle with accompanying EMG myotonia. In addition to routine nerve conduction studies and needle EMG, muscle cooling, exercise testing, and repetitive nerve stimulation (RNS) often are very helpful in differentiating among these disorders ( Box 39.2 ).
Myotonic Dystrophy, Type 1 | Myotonic Dystrophy, Type 2 | Myotonia Congenita: Dominant | Myotonia Congenita: Recessive | Sodium Channel Myotonia | Paramyotonia Congenita | Hyperkalemic Periodic Paralysis | Hypokalemic Periodic Paralysis | Andersen-Tawil Syndrome | |
---|---|---|---|---|---|---|---|---|---|
Age at onset | Teens to early adult | Teens to mid-adult | Infancy | Early childhood | Childhood to early teens | Infancy | Infancy to early childhood | Early teens | Childhood or early teens |
Inheritance | Autosomal dominant | Autosomal dominant | Autosomal dominant | Autosomal recessive | Autosomal dominant | Autosomal dominant | Autosomal dominant | Autosomal dominant | Autosomal dominant |
Gene defect | Protein kinase, chromosome 19q ( DMPK gene) | Cellular nucleic acid–binding protein, chromosome 3q ( CNBP gene) | Chloride channel, chromosome 7q ( CLCN gene) | Chloride channel, chromosome 7q ( CLCN gene) | Sodium channel, chromosome 17q ( SCN4A gene) | Sodium channel, chromosome 17q ( SCN4A gene) | Sodium channel, chromosome 17q ( SCN4A gene) | Calcium channel, chromosome 1q (type 1) ( CACNA1S gene) Sodium channel chromosome 17q (type 2) ( SCN4A gene) |
Potassium channel, chromosome 17q ( KCNJ2 gene) |
Myotonia | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | No |
Distribution of myotonia | Distal more than proximal | Proximal and distal | Generalized | Generalized | Proximal more than distal | Face, hands, thighs | Generalized, if present | None | None |
Periodic weakness | No | No | No | Yes, in some patients | No | Yes | Yes | Yes | Yes, in some patients |
Duration of weakness | N/A | N/A | N/A | N/A | N/A | Minutes to days | Minutes to days | Hours to days | Variable |
Progressive weakness | Yes | Yes | No | Rarely | No | No | Variable | Yes | Yes |
Extramuscular involvement | Yes | Yes | No | No | No | No | No | No | Yes |
Provocative factors | None | None | Cold | Cold | Potassium, delay after exercise | Cold, exercise, fasting | Cold, rest after exercise, emotional stress, fasting, potassium loading | Cold, rest after exercise, emotional stress, carbohydrates, alcohol | Rest after exercise, alcohol |
Alleviating factors | None | None | Exercise | Exercise | Unknown | Warming | Carbohydrates, mild exercise | Potassium, mild exercise | Mild exercise |
In some of the myotonic disorders, muscle cooling can be used to enhance myotonic discharges or bring out other characteristic abnormalities (see sections on Myotonia Congenita and Paramyotonia Congenita). Muscle cooling is best accomplished by wrapping the limb in a plastic bag and submerging it in ice water for 10–20 minutes. After the skin temperature is brought down to 20°C, needle EMG of the extremity is performed, with the electromyographer looking for abnormalities. Note that the patient should be watched closely, and the limb should always be removed from the ice water immediately if weakness develops.
Exercise testing can play an important role in the periodic paralysis and myotonic syndromes. Both short and prolonged exercise tests can be performed. In both, a routine distal compound muscle action potential (CMAP) is evoked with supramaximal stimulation (e.g., stimulating the ulnar nerve at the wrist, recording the abductor digiti minimi [ADM]). The nerve then is stimulated at 1-minute intervals for several minutes to ensure a stable baseline, before exercise is begun.
For the short exercise test, the patient is asked to rest for 5 minutes while a CMAP is recorded every minute, to ensure that the baseline is stable. The baseline may decrease just with rest in some patients, especially patients with a periodic paralysis disorder. After ensuring a stable baseline, the patient is then asked to perform maximal voluntary contraction for 5–10 seconds. Immediately afterward, a CMAP is recorded. The CMAP is recorded every 10 seconds until the CMAP recovers to baseline (typically 1–2 minutes) ( Fig. 39.2 ). If a decrement occurs after brief exercise and then recovers, the same procedure is repeated several times to see if the decrement continues to occur or habituates, which can help differentiate among some of the myotonic syndromes (discussed later).
For the prolonged exercise test, the recording procedure is the same. The patient is asked to rest for 5 minutes while a CMAP is recorded every minute to ensure the baseline is stable. The baseline may decrease just with rest in some patients, especially patients with a periodic paralysis disorder. After ensuring a stable baseline, the patient is asked to voluntarily contract his or her muscle maximally for 5 minutes, resting every 15 seconds for a few seconds. After the 5 minutes of exercise are complete, the patient relaxes completely. A CMAP is recorded immediately and then every 1–2 minutes for the next 40 minutes. In the periodic paralysis syndromes, both inherited and acquired, the CMAP amplitude may be unchanged or slightly larger immediately after prolonged exercise and then decline substantially over the next 20–40 minutes ( Fig. 39.3 ).
When performing the prolonged exercise test, the decrement can be calculated by comparing the nadir of the CMAP with the baseline value or comparing the nadir with the post-exercise peak, which often occurs early in the test. When these two methods have been studied, the peak to nadir method is preferred. This percentage is defined as the [peak – nadir]/peak × 100. An abnormality is defined as a decrement of >40% of amplitude or >50% of area. Amplitude or area can be used; there is no advantage to one over another. In patients in whom the pretest probability of having one of the periodic paralyses is 50% or less, an abnormal test raises the posttest probability that the patient truly has the disorder to over 95%. In the rare situation where the pretest probability is very high (>90%), then more liberal cutoffs of decrements, such as a decrement of >25% of amplitude or >35% of area, can be used.
Many of the same findings on exercise testing can also be found with RNS. Decrements are not uncommon with RNS in the myotonic syndromes. Although decrements may be seen with slow repetitive stimulation (3 Hz), they are more common with faster frequencies, typically 10 Hz. Abnormalities are not seen in all patients, although when present, they may suggest a specific syndrome.
When all the available electrophysiologic techniques are used, the correct diagnosis usually can be determined by answering several key questions ( Table 39.2 ):
Are routine nerve conduction studies normal?
On concentric needle EMG:
Are myotonic discharges present on needle EMG, and, if present, are they widespread or focal? If focal, what is the distribution, proximal or distal?
Are the MUAPs and recruitment pattern on EMG examination normal or abnormal? If the MUAPs and recruitment pattern are abnormal, are they myopathic or neurogenic?
Is there an effect of muscle cooling on the needle examination?
What does short exercise testing show?
What does prolonged exercise testing show?
What does RNS show?
Test | Myotonic Dystrophy, Type 1 | Myotonic Dystrophy, Type 2 | Myotonia Congenita: Dominant | Myotonia Congenita: Recessive | Sodium Channel Myotonia | Paramyotonia Congenita | Hyperkalemic Periodic Paralysis | Hypokalemic Periodic Paralysis | Andersen–Tawil Syndrome |
---|---|---|---|---|---|---|---|---|---|
Nerve conduction studies | Normal or decreased distal CMAPs | Normal | Normal | Normal | Normal | Normal | Normal between attacks; decreased CMAP amplitude during attack of weakness | Normal between attacks; decreased CMAP amplitude during attack of weakness | Normal |
EMG myotonia | ++D >P | ++D >P (upper extremity)D = P (lower extremity) | +++P and D | +++P and D | ++P and D | ++P and D | ++P and D, especially during attack | No myotonia | No myotonia |
EMG MUAPs | Myopathic D | Myopathic P | Normal | Usually NL, ±myopathic | Normal | Normal | Myopathic late in course | Myopathic late in course | Normal |
Muscle cooling (20°C) on electromyography | No effect | Unknown | May lead to increased duration of myotonic bursts; easier to elicit | No effect | Unknown | Transient dense fibrillation potentials that disappear below 28°C; myotonic bursts disappear below 20°C electrical silence, long-lasting muscle contracture at 20°C | No effect | No effect | No effect |
Short exercise | Drop in CMAP amplitude; quick recovery over 2 minutes; drop is smaller or does not persist on subsequent trials | Not well documented | Variable drop in CMAP amplitude; quick recovery over 2 minutes | Large drop in CMAP amplitude; delay in recovery may become progressive over time | Unknown | Normal or small increment in a warm muscle; marked drop in CMAP amplitude and very slow recovery over 1 hour in cooled muscle | No effect or transient increase in CMAP amplitude during an attack of weakness | No effect or transient increase in CMAP amplitude during an attack of weakness | No effect |
Prolonged exercise | Small decrement immediately after exercise, with recovery over 3 minutes | Unknown | Unknown | Small decrement immediately after exercise, with recovery over 3 minutes | Unknown | Moderate decrement immediately after exercise, maximal at 3 minutes, with slow recovery over 1 hour in cooled muscle | Most with initial increase in CMAP amplitude (∼35%); progressive drop in CMAP amplitude (∼50%) over 20–40 minutes with slow recovery over 1 hour | Most with initial increase in CMAP amplitude (∼35%); progressive drop in CMAP amplitude (∼50%) over 20–40 minutes with slow recovery over 1 hour | Most with initial increase in CMAP amplitude (∼35%); progressive drop in CMAP amplitude (∼50%) over 20–40 minutes with slow recovery over 1 hour |
10 Hz RNS | Decrement | Not well documented | Decrement | Large decrement | Not documented | Normal | Normal | Normal | Normal |
The myotonic dystrophies are among the most common of the myotonic muscle disorders. They are an autosomal dominant inherited, multisystem disorder characterized by progressive facial and limb muscle weakness, myotonia, and involvement of several organ systems outside of skeletal muscle. Also known as Steinert disease, myotonic dystrophy type 1 (DM1) is the most common; it is due to a defect in the protein kinase myotonin (dystrophia myotonica-protein kinase [ DMPK ]) gene on chromosome 19q. The gene defect itself is an unstable expansion of a CTG trinucleotide repeat in the untranslated region of the myotonin gene. Age of onset and severity of symptoms are variable and proportional to the size of the abnormal CTG trinucleotide repeats, which expands over subsequent generations. This phenomenon of “anticipation” results in an earlier onset and more severe course in subsequent generations. Myotonic dystrophy type 2 (DM2), also known as proximal myotonic myopathy (PROMM syndrome) and proximal myotonic dystrophy, is due to a defect in the CNBP (cellular nucleic acid–binding protein) gene (formerly known as ZNF9 , or zinc finger protein 9) on chromosome 3q. The gene defect itself is an unstable expansion of a CCTG repeat in intron 1 of the CNBP gene.
Patients with DM1 generally present in their late teens with mild distal weakness and delayed muscle relaxation, such as difficulty releasing their hand grip. This disorder is distinguished from other muscle disorders by the distal rather than proximal predominance of weakness, as well as the myotonia. The myotonia is less marked than in the myotonia congenitas. In classic myotonic dystrophy, patients experience stiffness that improves with repeated contractions. Thus, patients often report that repeated opening and closing of the hand results in a faster relaxation time with each grip. As the weakness progresses over years, the myotonic symptoms generally recede.
There is a distinctive clinical appearance characterized by bifacial weakness, temporal wasting, and frontal balding, resulting in a narrow, elongated face and horizontal smile, with ptosis, and distal muscle wasting and weakness ( Fig. 39.4 ). Patients with a smaller CTG trinucleotide repeat may not have the typical facial appearance. Weakness of neck flexion is also an early sign, and patients may notice difficulty lifting their head off the pillow or a tendency for the head to fall backwards during acceleration. DM1 is distinguished from many of the other myotonic disorders by the progressive distal weakness as well as involvement of several organ systems outside of skeletal muscle resulting in cataracts, cardiac conduction and pulmonary defects, endocrine dysfunction, testicular atrophy, hypersomnia, gynecologic problems, and, in some patients, mild to moderate cognitive impairment. As in the other myotonic and periodic paralysis syndromes, patients with myotonic dystrophy should be warned against potential anesthetic complications of succinylcholine and anticholinesterase agents.
The clinical examination in a patient suspected of having myotonic dystrophy is directed at recognition of the typical facies; demonstration of bifacial, neck flexor, and distal wasting and weakness; and demonstration of grip and percussion myotonia. Percussion myotonia can generally be elicited most easily over the thenar muscles and long finger extensors. Eyelid myotonia is not seen. Deep tendon reflexes often are reduced or absent in the lower extremities as the disease progresses. Slit lamp examination reveals posterior capsular cataracts, which early on have a characteristic multicolored pattern. Approximately 10% of cases are congenital, characterized by severe weakness and hypotonia at birth and intellectual disability. Children with the congenital form are floppy at birth, have a typical tented upper lip with poor sucking and swallowing, and often have contractures. Surprisingly, clinical myotonia is not present the first year of life. The congenital form nearly always is maternally inherited. In many cases, the mother may be so minimally affected that her diagnosis is not made until the infant is born with severe hypotonia and a myopathic facies.
Creatine kinase (CK) levels may be mildly to moderately elevated. Muscle biopsy typically reveals a mild increase in connective tissue, increased variation in fiber size, predominant atrophy of type I muscle fibers, an increase in central nuclei, ring fibers, and occasional small angulated fibers.
The clinical severity of DM1 is directly related to the number of CTG repeats. In normals, the number varies between 5 and 37, whereas in patients with DM1, the number of CTG repeats may range into the thousands. In individuals with a very small increase in the number of repeats (50–100), fewer than half of these people are symptomatic, and most have cataracts only. Symptoms and signs of DM1 are more typically present in individuals with over 100 repeats.
The electrophysiologic evaluation of DM1 ( Table 39.2 ) consists of routine nerve conduction studies, EMG, muscle cooling, and exercise testing.
Routine motor and sensory nerve conduction studies are normal as a rule. Generally, one motor and sensory nerve conduction study and F responses in an upper and lower extremity will suffice. A mild neuropathy has been described, perhaps secondary to the accompanying endocrine changes. Low CMAP amplitudes may be noted secondary to the distal myopathy in patients with severe disease.
Concentric needle EMG of at least one upper and one lower extremity should be performed, in addition to sampling facial and paraspinal muscles. Most but not all patients with DM1 will demonstrate myotonic discharges on EMG. In very mild cases (e.g., in patients with a small increase in the number of repeats), myotonic discharges may be difficult to find. Otherwise, myotonic discharges are generally most prominent in the distal hand, forearm extensor, foot dorsiflexor (tibialis anterior), and facial muscles but usually are not found in proximal muscles. The distribution of myotonic discharges follows the same pattern as the weakness. Myotonic discharges in DM1 consist of the classic waxing and waning muscle fiber action potentials ( Fig. 39.5A ). MUAP analysis may be difficult because of the myotonic discharges provoked by needle insertion or muscle contraction. However, careful examination reveals myopathic (low amplitude, short duration, polyphasic) MUAPs with early recruitment, which are generally noted in the forearm extensor and tibialis anterior muscles, consistent with the distal predominant weakness on clinical examination. Late in the course of DM1, MUAPs may become large and long.
Muscle cooling to 20°C has no appreciable effect on the EMG examination.
The short exercise test produces a drop in the CMAP amplitude immediately after exercise. If the CMAP then is recorded every 10 seconds up to 2 minutes, it recovers to baseline. If short exercise is repeated, the decremental response habituates after one or two cycles, with no further decrement in the CMAP occurring immediately after exercise.
RNS at 10 Hz produces a decrement similar to the short exercise test.
When electrophysiologic testing is completed, one has established the presence of myotonia with myopathic MUAPs on the needle examination, with a distal and facial muscle predominance. There is no effect of muscle cooling. The short exercise test demonstrates a decrement that recovers over 1–2 minutes and habituates with further cycles. This pattern of abnormalities strongly suggests the diagnosis of DM1. Note that when a patient presents with typical signs and symptoms of myotonic muscular dystrophy, muscle cooling, exercise testing, and RNS are not necessarily done on a routine basis but may be helpful in some clinical situations, when the diagnosis is still in question after standard nerve conduction studies and EMG needle examination are completed.
DM2 has many features in common with DM1. Like DM1, it is an autosomal dominant inherited muscle disorder recognized by a constellation of signs, including bifacial weakness, ptosis, progressive weakness, myotonia, and involvement of several organ systems outside of skeletal muscle. Patients typically present after the age of 40 with progressive weakness. Unlike myotonic dystrophy, however, the weakness involves predominantly proximal, as opposed to distal, muscles. The pattern of weakness typically involves the hip flexors and extensors, neck flexors, elbow extensors, and finger and thumb flexors. Anticipation is generally not seen between generations of affected family members. Like DM1, the multisystem involvement may include posterior capsular cataracts, frontal balding, testicular atrophy, and cardiac conduction defects. However, central nervous system involvement does not occur or is much less common.
Patients are recognized by their presentation of proximal greater than distal weakness, with mild bifacial weakness and ptosis in the setting of grip and percussion myotonia. Many patients have a peculiar intermittent pain syndrome in the thighs, arms, or back. CK may be mildly to moderately elevated, and the muscle biopsy reveals a nonspecific myopathic pattern, including increased variation in fiber size, small angulated fibers, pyknotic nuclear clumps, predominant atrophy of type II muscle fibers, and increased central nuclei. Rare cases of isolated elevated CK (“hyper-CKemia”) without other clinical or electrical abnormalities have been reported in DM2.
See Table 39.2 .
Routine motor and sensory nerve conduction studies are normal as a rule. Generally, one motor and sensory nerve conduction study and F responses in an upper and lower extremity will suffice.
Concentric needle EMG of at least one upper and one lower extremity and paraspinal muscles should be performed. In contrast to DM1, the myotonic discharges seen in DM2 tend to be predominantly waning potentials ( Fig. 39.5B ). These potentials are less specific than the classic waxing and waning discharges typically associated with myotonia. The distribution of the myotonic discharges in the upper extremities in DM2 is surprisingly more predominant in the distal than in the proximal muscles, similar to DM1. In the lower extremities, however, the pattern is different. Although myotonic discharges are present in distal muscles (e.g., the tibialis anterior), the number of myotonic discharges is approximately the same in distal and proximal muscles (e.g., tensor fascia lata). Thus the presence of myotonic discharges in the proximal lower extremity muscles is much more common in DM2 than DM1. Similar to DM1, the absence of myotonic discharges does not exclude the diagnosis of DM2. Complex repetitive discharges are noted occasionally. MUAP analysis reveals myopathic (low amplitude, short duration, polyphasic) MUAPs with early recruitment, which are generally noted in the proximal lower extremity muscles.
Once the nerve conduction studies and EMG are completed, the presence of myotonia with myopathic MUAPs has been established on needle examination, present primarily in proximal muscles of the lower extremity, and distal muscles of both the upper and lower extremities. Few disorders associated with myotonia have a proximal predominance with myopathic MUAPs. Rarely, prominent myotonic discharges, complex repetitive discharges, and myopathic MUAPs are noted in the very proximal muscles of patients with adult-onset acid maltase deficiency. In this disorder, however, the myotonic discharges are generally restricted to the paraspinal muscles. Myotonic discharges also may be seen in some patients with polymyositis, in whom abnormal spontaneous activity and MUAP changes are more prominent proximally. However, myotonic discharges are only infrequently seen in polymyositis. In the myotonia congenitas, myotonic discharges are noted mostly in proximal muscles as well, but with rare exception (i.e., some cases of recessive generalized myotonia congenita), there are no myopathic MUAP changes.
The effects of muscle cooling and the short and prolonged exercise tests have not been well described for this disorder. Short exercise testing in one patient personally examined by the authors revealed no drop in the CMAP amplitude recording from a distal hand muscle. This negative finding may reflect the proximal predominance of weakness.
Myotonia congenita is distinguished from the dystrophic muscle disorders by the lack of weakness in most patients and by the absence of extramuscular abnormalities. Two forms of myotonia congenita have classically been recognized. An autosomal dominant form, Thomsen disease, was first described in 1876 by Julius Thomsen, who was himself affected. Thomsen noted the great variability among his own affected family members; it was barely apparent in his mother and uncle, but very severe in his younger brother and sister. Muscular hypertrophy is common. An autosomal recessive form of generalized myotonia congenita was first described by Becker. The recessive form is characterized by later onset, marked myotonia, and muscular hypertrophy. Late in the course, there may be minor weakness and atrophy of the forearm and neck muscles, although it is still considered a nondystrophic syndrome. Some patients with recessive myotonia congenita also experience transient attacks of weakness that are relieved with exercise. Both the recessive and dominant forms of myotonia congenita arise from a skeletal muscle chloride channel-1 ( CLCN ) gene defect on chromosome 7q.
Other myotonia congenita phenotypes have also seen described, but with mutations in the muscle sodium α-subunit ( SCN4A ) gene on chromosome 17. These atypical myotonia congenitas include potassium-aggravated myotonia (PAM), myotonia permanens, myotonia fluctuans, and acetazolamide responsive myotonia. This is the same sodium channel gene with mutations that result in hyperkalemic periodic paralysis, paramyotonia congenita, and rare cases of hypokalemic periodic paralysis. These atypical myotonia congenitas are discussed later with the periodic paralyses and paramyotonia congenita disorders to which they are more closely related.
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here